
Agile Therapeutics AGRX
Quartalsbericht 2024-Q2
hinzugefügt 23.05.2026
Agile Therapeutics Operativer Cashflow 2011-2026 | AGRX
Operativer Cashflow Jährlich Agile Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.58 M | -35.9 M | -65.2 M | -47.3 M | -15.7 M | -16.9 M | -24.6 M | -23.3 M | -25.5 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -9.58 M | -65.2 M | -29.3 M |
Operativer Cashflow Vierteljährlich Agile Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.24 M | -2.48 M | - | -9.75 M | -10.1 M | -1.6 M | - | -34.4 M | -17.7 M | -14.8 M | - | -48.6 M | -30 M | -14.7 M | - | -30 M | -14.6 M | -7.88 M | - | -12.4 M | -7.34 M | -4.96 M | - | -13.8 M | -9.91 M | -5.72 M | - | -18.8 M | -11.9 M | -6.01 M | - | -20.4 M | -13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -1.6 M | -48.6 M | -14.5 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-5.46 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
-117 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-435 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
-19.1 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
4.93 M | $ 5.77 | -1.7 % | $ 85.7 M | ||
|
Cronos Group
CRON
|
25.9 M | $ 2.73 | -0.36 % | $ 1.05 B | ||
|
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
43.9 M | $ 34.17 | 3.55 % | $ 1.26 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
1.4 B | $ 5.4 | -1.28 % | $ 2 B | ||
|
Organogenesis Holdings
ORGO
|
-10.3 M | $ 2.66 | - | $ 337 M | ||
|
Pacira BioSciences
PCRX
|
189 M | $ 24.36 | 4.33 % | $ 1.13 B | ||
|
Canopy Growth Corporation
CGC
|
-166 M | $ 1.05 | 0.96 % | $ 113 M | ||
|
Solid Biosciences
SLDB
|
-156 M | $ 6.88 | 3.93 % | $ 602 M | ||
|
Aurora Cannabis
ACB
|
16 M | $ 3.46 | - | $ 190 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 1.06 | -3.64 % | $ 1.32 M | ||
|
Jupiter Wellness
JUPW
|
-6.4 M | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
7.91 M | $ 5.45 | 3.02 % | $ 3.37 B | ||
|
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
3.87 M | $ 1.11 | -0.89 % | $ 106 M | ||
|
Evolus
EOLS
|
-42.3 M | $ 6.25 | 2.63 % | $ 403 M | ||
|
Sundial Growers
SNDL
|
-155 M | $ 1.44 | -0.69 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
171 M | $ 9.13 | 8.05 % | $ 488 M | ||
|
Veru
VERU
|
-30 M | $ 2.31 | -1.7 % | $ 33.8 M | ||
|
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
-28.2 M | $ 23.46 | 0.09 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
-1.45 M | $ 0.76 | -0.12 % | $ 3.06 M | ||
|
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-45.8 M | $ 7.17 | 1.85 % | $ 283 M | ||
|
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-5.28 M | $ 0.68 | -6.88 % | $ 34 M | ||
|
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
2.32 B | $ 16.26 | -2.34 % | $ 18.9 B | ||
|
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-659 K | $ 0.76 | -4.74 % | $ 27.3 M | ||
|
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
148 K | $ 0.78 | 2.67 % | $ 3.35 M | ||
|
TherapeuticsMD
TXMD
|
-159 M | $ 2.11 | -0.47 % | $ 24.4 M |